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OBJECTIVE: Recently, it has been proposed that hereditary coagulation abnormalities leading to an in-
creased venous thrombosis risk may play a role in the development of preeclampsia. We tested this hypothe-
sis in women who have had preeclampsia compared with matched control subjects.
STUDY DESIGN: We conducted a case-control study of 163 women with preeclampsia during 1991-1996.
Control subjects were matched for age and delivery date. Patients and control subjects were tested for the
presence of factorV Leiden, prothrombin 20210A allele, protein C, protein S, and antithrombin deficiency.
Logistic regression methods were used for data analysis.
RESULTS: The prevalence of these genetic risk factors was similar in the patient group (12.9%) and the con-
trol group (12.9%; odds ratio, 1.0; 95% confidence interval, 0.5-3.9). Unexpectedly, we found a high preva-
lence of factor V Leiden in the control group (9.2%).
CONCLUSION: We found no differences in the prevalence of genetic risk factors of thrombosis in women
with preeclampsia compared with control subjects. (Am J Obstet Gynecol 1999;181:975-80.)
Key words: Preeclampsia, hereditary coagulation abnormalities, factor V Leiden, prothrombin
2021OA allele, antithrombin deficiency
Preeclampsia, a pregnancy-specific syndrome clinically
defined äs elevated blood pressure and proteinuria, re-
mains an important cause of maternal and fetal morbid-
ity and mortality despite intensive research.1· 2 Its patho-
genesis is unknown, but genetic, immunologic factors
and abnormal placentation have been proposed to play a
causative role. Abnormal placentation early in pregnancy
might result in restricted blood flow to the placental-fetal
unit and subsequent liberation of cytotoxic factors. These
factors may result in endothelial damage clinically mani-
fested by a systemic maternal syndrome.3·4
Recently, abnormal placentation has been associated
with an increased tendency toward thrombosis.5· 6 The
tendency toward thrombosis in women with preeclamp-
sia might be the result of the combination of an acquired
risk factor (pregnancy) with a genetic risk factor for ve-
nous thrombosis. Recently, the discovery of common ge-
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neue risk factors for venous thrombosis, such äs factor V
Leiden7 and prothrombin 2021 OA allele,8 resulted in the
hypothesis that genetic risk factors of thrombosis might
play a causative role in the development of preeclampsia.
Therefore the aim of this study was to compare the
prevalence of inherited risk factors for thrombosis, in-
cluding factor V Leiden, prothrombin 20210A allele,
protein C, protein S, and antithrombin deficiency, in
women who have had preeclampsia in their first preg-
nancy and in matched control subjects with an unevent-
ful pregnancy.
Material and methods
Study design. Women who had preeclampsia during
their first pregnancy were selected from a Computer
database and patient charts. Included were women who
were delivered of their neonates on the obstetric Service
of the Leiden University Medical Center (n = 117) or at
the St Joseph Hospital Veldhoven (n = 81) in the period
from January l, 1991, through December 31, 1996. The
study was approved by the Committee on Ethics in
Human Research of both hospitals.
Preeclampsia and eclampsia were defined after the
completion of pregnancy by means of strict criteria9: rise
of blood pressure (>30 mm Hg systolic or >15 mm Hg di-
astolic over values in the first 20 weeks or, if blood pres-
sure was unknown, before 20 weeks of gestation); late-
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Table I. Description of medical reasons for in-hospital
delivery of control group and prevalence of factor V and














































































pregnancy hypertension (defined äs an absolute blood
pressure >140/90 mm Hg); and proteinuria (>2+ [100
mg/dL] on a voided specimen or >1+ [30 mg/dL] on a
catheterized specimen). All women defined äs having
preeclampsia fulfilled the criteria of a rise of blood pres-
sure äs described. Of these women, 4 with preeclampsia
had an absolute blood pressure in late gestation of
<140/90 mm Hg (average ± SEM, 131/85 ± 4/0 mm Hg).
Severe preeclampsia is defined äs an absolute diastolic
blood pressure of >110 mm Hg and proteinuria (>2+
[100 mg/dL]) on a catheterized specimen at admission.
Excluded from the study and control groups were
women who had multiple pregnancies, chronic hyper-
tension, renal disease, diabetes, collagen vascular dis-
eases, cancer, or thrombosis before their first pregnancy.
None of the women with preeclampsia had venous
thrombosis before or during the first pregnancy, and
thus none were excluded on the basis of this criterion.
We found 198 consecutive patients that were eligible for
the study. Of these women, 163 (82%) were willing to
participate in the study; 35 (18%) women with
preeclampsia did not enter the study for the following
personal reasons (18 from the Leiden University Medical
Center and 17 from the St Joseph Hospital Veldhoven):
were unwilling to spend time (n = 10), had an unknown
address (n = 6), were unwilling to undergo venipuncture
(n = 3), expected insurance problems after deoxyribonu-
cleic acid analvsis (n = 7), had a current pregnancy (n =
3), had language problems (n = 2), or did not want to be
reminded of the period of preeclampsia (n = 4).
Control subjects were selected from the same Com-
puter database according to the following criteria: first
pregnancy, no rise in blood pressure, no hypertension or
proteinuria, similar age (±5 years), no biologic relation-
ship, and a delivery date äs close äs possible to the deliv-
ery date of a patient. The exclusion criteria applied were
the same äs those for the patients. A total of 229 control
subjects were asked to enter the study, and 66 (29%) re-
fused for the following reasons (46 from the Leiden
University Medical Center and 20 from the St Joseph
Hospital Veldhoven): were unwilling to spend time (n =
19), had an unknown address (n = 23), were unwilling to
undergo venipuncture (n = 7), expected insurance prob-
lems after deoxyribonucleic acid analysis (n = 7), had a
current pregnancy (n = 7), or had a language problem (n
= 3). A detailed description of the reasons for delivery in
the hospital of the control group is provided in Table I.
Clinical and demographic data are summarized in Table
II. Intrauterine growth restriction was defined according
to the birth weights äs <5th percentile, äs described by
Kloosterman.10
After informed consent was obtained, blood samples
were drawn, and a Standard questionnaire was completed
containing questions about personal and family history
of venous thrombosis. This was done because the willing-
ness to participate in the study (especially in the control
group) might be influenced by the perception of an in-
creased risk known through a family history of venous
thrombosis. We called a family history positive when ve-
nous thrombosis was reported in one or more first- or
second-degree relatives of the patient or control subject.
The questionnaire also included questions about a family
history of hypertension, height and weight, and smoking
habits.
Laboratory studies. Blood was collected from the ante-
cubital vein into Monovette ttibes (Sarstedt, Nümbrecht,
Germany) containing 0.106 mol/L trisodium citrate.7· n
Plasma was prepared by centrifugation for 10 minutes at
2000g at room temperature and stored at -70°C in 1.5-
mL volumes until used. High-molecular-weight deoxyri-
bonucleic acid was isolated from leukocytes and stored at
4°C. Factor V Leiden,12 prothrombin 20210A allele,13
protein C antigen,14 and total protein S antigen1·5 levels
were determined äs described elsewhere. Antithrombin
activity was measured with the antithrombin kit
(Chromogenix AB, Mölndal, Sweden) on an ACL 300.
The technician was blinded to the Status of the sample
(ie, whether it was from a woman who had preeclampsia
or a control subject). The results are expressed äs pre-
sent or absent for factor V Leiden and prothrombin
20210A allele or in unils per milliliter, where l U refers
to the activity or antigen present in l m L of pooled nor-
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Table II. Clinical and demographic data of women who had preeclampsia and matched control subjects
Maternal age al delivery (y)
Gestational age at delivery (d)
Systolic blood pressure at <20 weeks' gestation (mm Hg)
Diastolic blood pressure at <20 weeks' gestation (mm Hg)
Systolic blood pressure at >20 weeks' gestation (mm Hg)























Data are mean ± SEM.
*P< .05, versus control subjects.
Table III. Number and frequency of subjects with factor V Leiden and prothrombin 20210A allele
Women with preeclampsia in Control subjects
firsl pregnancy (n = 1 63) (n - 163)
Factor V Leiden







% 95 % conßdence interval
9.2 1.07 (0.51-2.25)
3.7 0.83 (0.25-2.77)
mal plasma (l U/mL = 100%), for protein C, protein S,
and antithrombin. The criteria for the diagnosis of pro-
tein deficiencies were plasma levels <0.63 U/mL for pro-
tein C and total protein S and <0.80 U/mL for an-
tithrombin (combined with normal values for
prothrombin and prothrombin time to exclude vitamin
K deficiency). All subjects with positive lest results for fac-
tor V Leiden or prothrombin 2021OA allele or suspected
of a protein C, protein S, or antithrombin deficiency
were seen on a second occasion for further evaluation.
All subjects thought to have a protein C, protein S, or an-
tithrombin deficiency after the first analysis were, on the
second occasion, at least 12 weeks post partum and/or had
stopped coumarin therapy for at least 12 weeks.
Statistical analysis. We calculated relative risks äs esti-
mates of the odds ratios by simple cross-tabulation for
factor V Leiden or prothrombin 20210A allele. We ana-
lyzed women who had preeclampsia and several risk fac-
tors, including a family history of thrombosis and hyper-
tension, body mass, smoking, and coagulation mutations,
versus control subjects by means of unconditional logistic
regression techniques that allow adjustments for these
factors simultaneously. Demographic and clinical data
are presented äs patient group means with an SE or SD.
Results
A total of 163 women with preeclampsia entered the
study; 99 were delivered of their neonates in the Leiden
University Medical Center and 64 in the St Joseph
Hospital Veldhoven. The frequency of the factor V
Leiden and prothrombin 20210A allele was not different
between women who had preeclampsia and their control
subjects (Table III). No differences were found in the fre-
quency of factor V Leiden between the Leiden University
Medical Center and the St Joseph Hospital Veldhoven for
women who had preeclampsia (9 [9.1%] and 7 [10.9%],
respectively) and for the control subjects (8 [8.1%] and 7
[10.9%], respectively). Similar results were found for the
prothrombin 20210A allele in subjects from the Leiden
University Medical Center versus St Joseph Hospital
Veldhoven for women who had preeclampsia (3 [3.0%]
and 2 [3.1%], respectively) and control subjects (4
[4.0%] and 2 [3.1%], respectively). In all women who
had positive test results for either factor V Leiden or pro-
thrombin 20210A allele, results were confirmed in a sec-
ond blood sample; all were heterozygous for the muta-
tion. After a second analysis, which included the further
evaluation of subjects with initially low levels of protein C
(n = 2), total protein S (n = 5), or antithrombin (n = 3),
persistently low levels were detected in only l woman di-
agnosed with an antithrombin deficiency, who had
preeclampsia in her first pregnancy. The discrepancy be-
tween results of the first and second analyses can be ex-
plained by pregnancy, postpartum period, coumarin use,
or hormone treatment at the time of first blood collec-
tion. Overall, the prevalence of genetic risk factors for
thrombosis (any coagulation disorder) was similar in
both groups (12.9% in the patients and 12.9% in the
control subjects; odds ratio, 1.00; 95% confidence inter-
val, 0.52-3.88).
The unexpectedly high frequency of factor V Leiden
in our control group was further analyzed for factors that
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(No ) lo control
Variable subjects (No )
Thrombosis in family 36/37
Hypertension in family 93/70
Body mass index 76/57
Smoking 18/29




0 96 (0 40-2 88)
166(106-1008)
151 (095-811)
0 54 (0 28-2 42)
1 19 (0 55-4 38)
Simultaneous adjustment for different vanables was made m a
logisüc model
rnight have influenced this increased prevalence A posi-
tive family history of venous thrombosis (Table IV) was
found äs frequently among women who had preeclamp-
sia dunng their first pregnancy (n = 36) äs among the
matched control subjects (n = 37), mdicatmg no differ-
ences m baselme nsk After adjustment for positive fam-
ily history for thrombosis, hypertension, body mass
mdex, smokmg, and the factor V Leiden mutation, the
odds ratios for preeclampsia and factor V Leiden re-
mamed essentially the same We found an almost 2-fold
higher nsk for preeclampsia m women with a positive
farmly history of hypertension
Further analysis showed that important chnical out-
come vanables were associated with genetic nsk factors
of thrombosis First, control subjects with factor V Leiden
(n = 15) were dehvered at a lower gestational age than
control subjects without factor V Leiden (n = 148, 269 ±
20 [SD] days vs 279 ±17 days, respectively), and thus
their babies had lower birth weights (2997 ± 581 g vs 3303
± 560 g) No differences m gestational age or birth
weight were found among women with preeclampsia
with positive or negative test results for factor V mutation
(n = 16, 238 ± 26 days vs 240 ± 35 days, 1912 ± 867 g vs
1941 ± 951 g, respectively)
Second, the frequency of factor V Leiden was also not
greater in women who had severe preeclampsia (2/37)
than in control subjects (15/163, odds ratio, 051, 95%
confidential interval, 0 12-2 67) Similar results were
found by usmg gestational age (dehvery before 238 days)
to mdicate severe preeclampsia (7/76, hypertension and
protemuria defined äs for preeclampsia, odds ratio, l 0,
95% confidential interval, 0 4-3 5)
Third, none of the women in whom thrombosis devel-
oped (n = 5) after their first pregnancy, mcluding 4
women who had preeclampsia and l control subject, had
positive test lesults for factor V Leiden, prothrombm
20210A allele, or antithrombin deficiency (follou-up
median, 26 months, ränge, 0 5-76 months)
Fourth, none of the women who had eclampsia (n =
11), of whom 8 were in the antepaitum peuod and "*>
were m the postpartum penod, had positive results for
one of the coagulation mutations
Fifth, intrautenne growth restnction was found m 18
women who had preeclampsia, of whom l had positive
results for both factor V Leiden and prothrombm
20210A allele, and 9 control subjects, of whom none
were positive for a coagulation mutation There were no
staüstical differences for coagulation deficiencies among
patients and control subjects
Sixth, intrautenne fetal death was found m 18 women
who had preeclampsia, of whom 2 women had positive
test results for prothrombm 2021OA allele
Comment
We found no differences m the prevalence of inher-
ited nsk factors for venous thrombosis, mcluding factor
V Leiden, prothrombm 20210A allele, and protem C,
protem S, and antithrombin deficiencies, m women who
had preeclampsia m their first pregnancy and in control
subjects with an uneventful pregnancy This is in contrast
with data from previous published studies 6 16,17 One ex-
planation is the unexpectedly high frequency of factor V
Leiden in the control group (9 2%) in this study We
therefore compared the frequency of the factor V Leiden
mutation among women who had preeclampsia with that
of a different control group exammed previously18 This
group consisted of a subset of the original control group
of the Leiden Thrombophilia Study In that study 474
consecutive patients with thrombosis were matched with
474 control subjects who either were acquamtances
asked to participate by the patients or were partners of
the patients From these control groups we selected, for
the current analysis, women who had expenenced at
least l pregnancy, had no history of venous thrombosis,
were premenopausal, were not pregnant, were not in the
puerperium, and had no recent miscarriäge (total
women included, 105) 18 We found a higher frequency
for factor V Leiden m women who had preeclampsia ver-
sus these control subjects (odds ratio, 3 70, 95% confi-
dence interval, l 05 13 03) When we compare the fre-
quency of the prothrombm 2021 OA allele among women
who had preeclampsia with that of the same alternative
control groupi8 (total women included, 105, prothrom-
bm 20210A allele positive, 3), no differences m fre-
quency were found for prothrombm 20210A allele (odds
ratio, l 08, 95% confidence interval, 0 25 4 60) Dizon-
Townson et al16 reported a frequency of factor V Leiden
in an American obstetric populaüon of 4 2% (n = 403),
which is similar to the frequency described m the Leiden
Thrombophilia Study and a large Amencan study (3%
4%)''' and almost 3 times lower than the frequency ob-
ser\ed in the control subjects recruited m our studv
Di/on-Townson et al l ( ) also reported a frequency of factoi
\ I eiden of 3% m an unselected group of gravid women
Ho\\e\ei higher hequenciei o( factoi V Leiden have also
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been described by Pauer et al21; frequencies of 9.2%
(8/87 of an unselected group of healthy women with no
history of fetal losses) and äs high äs 12% have been re-
ported in some selected groups with a history of venous
thrombosis or pulmonary embolism.22
If the high frequency of factor V Leiden was too high
in our control group, we can speculate about selection
bias. We estimated that if all women who refused to enter
the study had negative lest results for factor V Leiden we
still would have found a frequency of 6.6% (15/229).
Again, no differences would then be apparent between
patients and control subjects. Moreover, given the reason
for not entering these control subjects into the study, this
seems unlikely to explain the high prevalence of factor V
Leiden in the control subjects of our study. No statistical
differences were found for the reasons for refusal to
enter the study among patients and control subjects. A
second possibility is that women who undergo delivery in
a hospital are different from all women giving birth; in
The Netherlands about one third of the deliveries are at
home. Although control subjects with positive lest results
for factor V Leiden had a relatively high frequency of
preterm labor (3/15), no differences were found among
patients and control subjects when the subjects with
preterm labor were excluded (odds ratio, 1.34; 95% con-
fidence interval, 0.61-4.97). As described in Table IV, we
also found no difference between the 2 groups for family
history of thrombosis nor was there a difference in family
history for thrombosis among control subjects of our
study and the alternative control group described previ-
ously in this section, with a lower frequency of the factor
V Leiden mutation (n = 37 and 23, respectively; odds
ratio, 1.0; 95% confidence interval, 0.24-3.33).18
Nevertheless, we cannot rule out the possibility that
women who undergo delivery in the hospital are not fully
representative of the prevalence of heritable coagulation
mutations of all gravid women.
Another explanation why others found a difference in
the frequency of coagulation abnormalities in both
women with preeclampsia and the control subjects is that
they found a particularly high incidence of coagulation
abnormalities among the patients. Dekker et al17 re-
ported a 16% rate of activated protein C resistance in se-
vere-onset preeclampsia. Bertina et al7 have shown that
80% to 100% of persons with laboratory-confirmed acti-
vated protein C resistance are either heterozygous or ho-
mozygous for the factor V Leiden mutation. As suggested
by Dizon-Townson et al,16 the high rate of activated pro-
tein C resistance might be the result of a different defini-
tion of pregnancy-induced hypertension; 39% had
chronic hypertension versus 3.1% in this study of women
with preeclampsia, and 89% were nulliparous.17
Differences in definition, methods, and cutoff levels used
might explain the high frequency of activated protein C
resistance. However, Dizon-Townson et al16 described a
frequency of factor V Leiden that was similar to that
found in our study (n = 158, 8.9%) in women with severe
preeclampsia. Recently, Kupfermine et al6 reported a
prevalence of 53% of inherited thrombophilia in women
with severe preeclampsia, including 26% (9/34) with fac-
tor V Leiden. Furthermore, it is unlikely that our results
are explained by the geography of our population be-
cause the frequency of factor V Leiden was similar in the
population of 2 different hospitals from 2 different re-
gions of the country. Both groups had an identical ethnic
origin (96% white), which was very similar to that de-
scribed by Dizon-Townson et al16 (94% white).
Several important outcome variables of preeclampsia
were evaluated and associated with coagulation muta-
tions, including thrombosis, eclampsia, intrauterine
growth restriction, and intrauterine fetal death. We did
not find an association between these variables and an in-
creased frequency of genetic risk factors (factor V
Leiden, prothrombin 20210A allele, and antithrombin
deficiency). However, the number of specific outcome
variables is small, and because of the study design, the
Undings are post hoc.
The frequency of thrombosis is relatively high (1.5%)
in the 2 study groups (identical in patients and control
subjects) compared with what has been reported previ-
ously.23 This might be explained by the group of women
studied; 52% of the women who had preeclampsia were
delivered by cesarean compared with 6% in the control
group (odds ratio, 16.2; 95% confidence interval, 8.0-9.3
χ 106). Furthermore, in this study the frequency of
thrombosis is described by using a questionnaire. All
women who had thrombosis after their first pregnancy
explained that the diagnosis was confirmed with ultra-
sonography or ventilation-perfusion scanning. A referral
bias in the perception of increased risk that might lead
doctors to intensify their diagnostic and referral behavior
for women who have been sick during pregnancy cannot
be excluded. In this study thrombosis did not develop in
any of the women with genetic risk factors for thrombosis
during the first pregnancy. The estimate of thrombotic
risk for women with a factor V Leiden mutation varies
from 0.3% to 2% of pregnancies.23· 24 Therefore these
data do not support the use of thromboprophylaxis in
first pregnancies of women with a factor V Leiden or pro-
thrombin 2021OA allele because the necessary use of an-
ticoagulants will increase fetal and maternal morbidity
and mortality rates, whereas only a few thrombotic events
would be prevented. The benefit-to-risk ratio of using
thromboprophylaxis in pregnancies of women with a ge-
netic coagulation disorder and other genetic or acquired
risk factors, including severe preeclampsia, needs to be
evaluated in large, prospective, randomized, controlled
studies.20
In conclusion, in our case-control study we found no
increased frequency of the genetic risk factors for throm-
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bosis in women who had preeclampsia in their first preg-
nancy compared with control subjects with an uneventful
pregnancy m the hospital Unexpectedly, we found a
high frequency of factor V Leiden m the control group
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